Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836017 · ClinicalTrials.gov registry record
CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 1,046
- Enrollment target
NCT00836017: Completed study, sponsored by Allergan.
NCT00836017 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 1,046 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836017 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 1,046 participants
- Enrollment target
Study Summary
This study is an observational trial which will measure the efficacy of onabotulinumtoxinA in treating Cervical Dystonia.
Primary Outcome
TWSTRS is an assessment scale used to measure the impact of cervical dystonia on patients. The score is comprised of 3 subscales: Severity, Disability, and Pain, each of which is scored independently. The total of these 3 subscales comprises the TWSTRS total score which is scored from 0 (least symptoms) to 85 (worst symptoms). Higher scores indicate a greater degree of symptom severity.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-08 |
What the finished NCT00836017 record still lists
NCT00836017 is an observational study that tracks outcomes without assigning an intervention. Its 1,046 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT00836017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00836017 about?
NCT00836017 is a clinical study titled "CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy". This study is an observational trial which will measure the efficacy of onabotulinumtoxinA in treating Cervical Dystonia.
What is the current status of trial NCT00836017?
This trial is currently completed. The enrollment target is 1,046 participants. The study started on 2009-01. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00836017?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT00836017?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia